Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Genmab ADR’s stock clocked out at $33.65, up 1.78% from its previous closing price of $33.06. In other words, the price has increased by $1.78 from its previous closing price. On the day, 1.37 million shares were traded. GMAB stock price reached its highest trading level at $33.67 during the session, while it also had its lowest trading level at $33.255.
Ratios:
To gain a deeper understanding of GMAB’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.60. For the most recent quarter (mrq), Quick Ratio is recorded 6.01 and its Current Ratio is at 6.03. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 18 ’25 when GENMAB A/S bought 212,177 shares for $97.00 per share. The transaction valued at 20,581,169 led to the insider holds 71,946,801 shares of the business.
GENMAB A/S bought 66,264 shares of GMAB for $6,427,608 on Dec 19 ’25. The 10% Owner now owns 72,013,065 shares after completing the transaction at $97.00 per share. On Dec 17 ’25, another insider, GENMAB A/S, who serves as the 10% Owner of the company, bought 150,795 shares for $97.00 each. As a result, the insider paid 14,627,115 and bolstered with 71,734,624 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMAB now has a Market Capitalization of 20860790784 and an Enterprise Value of -1197262080. As of this moment, Genmab’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.29, and their Forward P/E ratio for the next fiscal year is 21.48. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.77 while its Price-to-Book (P/B) ratio in mrq is 3.60. Its current Enterprise Value per Revenue stands at -0.311 whereas that against EBITDA is -0.813.
Stock Price History:
The Beta on a monthly basis for GMAB is 0.89, which has changed by 0.60641396 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, GMAB has reached a high of $33.65, while it has fallen to a 52-week low of $17.24. The 50-Day Moving Average of the stock is 9.22%, while the 200-Day Moving Average is calculated to be 35.56%.
Shares Statistics:
It appears that GMAB traded 2.12M shares on average per day over the past three months and 1613030 shares per day over the past ten days. A total of 615.99M shares are outstanding, with a floating share count of 615.99M. Insiders hold about 0.00% of the company’s shares, while institutions hold 10.31% stake in the company. Shares short for GMAB as of 1764288000 were 11896539 with a Short Ratio of 5.60, compared to 1761868800 on 10539384. Therefore, it implies a Short% of Shares Outstanding of 11896539 and a Short% of Float of 1.95.
Earnings Estimates
The dynamic stock of Genmab ADR (GMAB) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.31, with high estimates of $0.31 and low estimates of $0.31.
Analysts are recommending an EPS of between $2.01 and $1.78 for the fiscal current year, implying an average EPS of $1.92. EPS for the following year is $1.51, with 5.0 analysts recommending between $2.58 and $1.01.
Revenue Estimates
In. The current quarter, 8 analysts expect revenue to total $6.55B. It ranges from a high estimate of $7.21B to a low estimate of $6.12B. As of. The current estimate, Genmab ADR’s year-ago sales were $6.44BFor the next quarter, 8 analysts are estimating revenue of $6.1B. There is a high estimate of $6.61B for the next quarter, whereas the lowest estimate is $5.24B.
A total of 16 analysts have provided revenue estimates for GMAB’s current fiscal year. The highest revenue estimate was $25.25B, while the lowest revenue estimate was $23.04B, resulting in an average revenue estimate of $23.78B. In the same quarter a year ago, actual revenue was $21.53BBased on 14 analysts’ estimates, the company’s revenue will be $27.49B in the next fiscal year. The high estimate is $29.32B and the low estimate is $24.82B.
